Home LiteratureArticle Details
PMID: 17131307 Published · ppublish English Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON).

International journal of cancer ·Vol. 120 ·No. 4 ·2007-02-15 ·Pages 868-74

van Iersel CA, de Koning HJ, Draisma G, Mali WP, Scholten ET, Nackaerts K, Prokop M, Habbema JD, Oudkerk M, van Klaveren RJ

Abstract

A method to obtain the optimal selection criteria, taking into account available resources and capacity and the impact on power, is presented for the Dutch-Belgian randomised lung cancer screening trial (NELSON). NELSON investigates whether 16-detector multi-slice computed tomography screening will decrease lung cancer mortality compared to no screening. A questionnaire was sent to 335,441 (mainly) men, aged 50-75. Smoking exposure (years smoked, cigarettes/day, years quit) was determined, and expected lung cancer mortality was estimated for different selection scenarios for the 106,931 respondents, using lung cancer mortality data by level of smoking exposure (US Cancer Prevention Study I and II). Selection criteria were chosen so that the required response among eligible subjects to reach sufficient sample size was minimised and the required sample size was within our capacity. Inviting current and former smokers (quit <or= 10 years ago) who smoked >15 cigarettes/day during >25 years or >10 cigarettes/day during >30 years was most optimal. With a power of 80%, 17,300-27,900 participants are needed to show a 20-25% lung cancer mortality reduction 10 years after randomisation. Until October 18, 2005 11,103 (first recruitment round) and 4,325 (second recruitment round) (total = 15,428) participants have been randomised. Selecting participants for lung cancer screening trials based on risk estimates is feasible and helpful to minimize sample size and costs. When pooling with Danish trial data (n = +/-4,000) NELSON is the only trial without screening in controls that is expected to have 80% power to show a lung cancer mortality reduction of at least 25% 10 years after randomisation.

MeSH Terms
Aged Belgium/epidemiology Clinical Protocols Control Groups Female Follow-Up Studies Humans Lung Neoplasms/diagnostic imaging,prevention & control Male Mass Screening Middle Aged Neoplasm Staging Netherlands/epidemiology Patient Selection Risk Factors Sample Size Tomography, X-Ray Computed
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
van Iersel Carola A
Department of Public Health, Erasmus MC, Rotterdam, The Netherlands. c.vaniersel@erasmusmc.nl
de Koning Harry J
Draisma Gerrit
Mali Willem P T M
Scholten Ernst Th
Nackaerts Kristiaan
Prokop Mathias
Habbema J Dik F
Oudkerk Mathijs
van Klaveren Rob J
Article Info
Journal
International journal of cancer
Abbr.
Int J Cancer
ISSN
0020-7136
Published
2007-02-15
Pages
868-74
Language
English
Region
United States
NLM ID
0042124
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com